SmithRx is a technology company.
SmithRx has raised $99.0M across 4 funding rounds.
Key people at SmithRx.
SmithRx has raised $99.0M in total across 4 funding rounds.
Key people at SmithRx.
SmithRx has raised $99.0M in total across 4 funding rounds.
SmithRx's investors include First Round Capital, F-Prime Capital Partners, Moderne Ventures, Venrock, Jonathan Bush, Kevin Nazemi, Daffy, Footprint Coalition, Pareto Holdings, Presight Capital, rocketship.vc, Shaan's All Access Fund.
SmithRx is a San Francisco-based technology company founded in 2016 that operates as a modern Pharmacy Benefits Manager (PBM), delivering prescription drug benefits through a radically transparent, 100% pass-through pricing model.[1][2][3][5][7] It serves employers, organizations, and members by providing the lowest-cost medication pathways via cutting-edge technology, including custom portals, mobile access, and programs like Connect 360 for autoimmune treatments, achieving average pharmacy cost reductions of 30% and up to 95% savings on high-cost drugs with $0 copays.[1][3][4][6][7] This solves core problems in the opaque U.S. PBM industry—hidden fees, rebate retention, and complexity—through auditable pricing, all manufacturer rebates passed directly to clients, and white-glove service on a single, reliable platform.[2][3][5]
SmithRx was founded in 2016 by Jake Frenz, driven by his personal healthcare struggles: caring for his father with cancer at age 22, facing his own cancer diagnosis that risked leg amputation, and later managing specialty drugs for his ill mother.[5] These experiences exposed systemic U.S. healthcare failures like opacity and unfair pricing in pharmacy benefits, inspiring Frenz to launch a transparent PBM alternative prioritizing employers' and patients' interests.[2][5][7] Early traction came from building a state-of-the-art platform with pass-through rebates, drug cost guarantees, and concierge service; by implementing HIPAA-compliant Salesforce tools in under 10 weeks, SmithRx gained reliable sales forecasting, pipeline visibility, and 100% team adoption without disruption.[2]
SmithRx rides the wave of PBM modernization, targeting a $500B+ U.S. pharmacy benefits market plagued by opacity, where traditional players retain rebates and inflate costs amid rising drug prices and biosimilar adoption.[1][3][5][7] Timing aligns with post-2020 scrutiny on healthcare transparency (e.g., via laws like the Inflation Reduction Act) and tech-driven disruption in fintech-adjacent healthtech, enabling smaller, agile PBMs to capture share from incumbents.[7] Favorable forces include biosimilar launches reducing specialty drug costs and employer demands for cost control; SmithRx influences the ecosystem by pioneering tech-enabled equity, inspiring competitors, and proving scalable savings for mid-market employers.[1][2][6][7]
SmithRx is poised for accelerated growth through biosimilar expansions, AI-enhanced pathways, and potential enterprise scaling, building on 2024-2025 momentum like 30% cost cuts and $14.5M savings pilots.[1][6][7] Trends like value-based care, regulatory rebate reforms, and healthtech consolidation will amplify its transparent model, potentially positioning it for IPO or acquisition as pre-IPO interest grows.[7] Its influence may evolve from niche disruptor to category leader, redefining PBMs around technology and trust—echoing its founding mission to humanize pharmacy benefits for all.[5]
SmithRx has raised $99.0M across 4 funding rounds. Most recently, it raised $60.0M Series C in January 2024.